RxDoctor Payments DataLook up a doctor →

Paul Opsahl, MD

Family Medicine · Waynesville, OHNPI 1619953742

Payments from drug & device makers

$473,663in general payments, 2019–2025

Across 519 payments — averaging $912.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk AS$188K
  • Novartis$145K
  • Eli Lilly$137K
  • AstraZeneca$2K
  • AbbVie$546
  • Lilly USA, LLC$523
  • plus $756 from 14 others
$26,708in research payments, 2019–2025

Across 1 payment — averaging $26,708 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$27K

What the payments were for

  • Food & beverage$1,824100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$473,663 in reported general payments places this provider in the 95th percentile of 3,983 family medicine providers in Ohio.

See all family medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$51,906
Medicare patients
187
Services billed
538

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban84$53,891
OzempicSemaglutide44$40,879
MounjaroTirzepatide30$30,443
TrulicityDulaglutide22$25,488
JardianceEmpagliflozin14$19,714
JanuviaSitagliptin Phosphate19$19,198
Trelegy ElliptaFluticasone/Umeclidin/Vilanter26$16,645
Bydureon BciseExenatide Microspheres14$14,636
OxycontinOxycodone Hcl13$6,994
Gabapentin215$4,464
Atorvastatin Calcium525$3,879
SymbicortBudesonide/Formoterol Fumarate11$3,493
Tamsulosin Hcl185$2,834
Quetiapine Fumarate79$2,494
Lantus SolostarInsulin Glargine,hum.Rec.Anlog16$2,273

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$523$55,93052 claims
PfizerEliquis$27$53,89184 claims
Novo NordiskOzempic$94$40,87944 claims
Boehringer IngelheimJardiance$13$19,71414 claims
MerckJanuvia$127$19,19819 claims
GSKTrelegy Ellipta$58$16,64526 claims
AstraZenecaSymbicort$2,087$3,49311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,983 family medicine providers in Ohio.

Other family medicine in Waynesville

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →